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Purpose
The purpose of this study was to conduct a cost effectiveness analysis of strategies designed
to improve national cervical cancer screening rates, along with a distributional cost effec-
tiveness analysis that considers regional disparities. 
Materials and Methods
Cost effectiveness analysis was conducted using a Markov cohort simulation model, with
quality adjusted life years as the unit of effectiveness. The strategies considered were current
(biennial Papanicolaou smear cytology of females aged 20 or above), strong screening rec-
ommendation by mail to target regions (effect, 12% increase in screening uptake; cost, 1,000
Korean won per person), regular universal screening recommendation by mail (effect, 6%
increase in screening uptake; cost, 500 Korean won per person), and strong universal screen-
ing recommendation by mail (effect, 12% increase in screening uptake; cost, 1,000 Korean
won per person). Distributional cost effectiveness analysis was conducted by calculating the
cost effectiveness of strategies using the Atkinson incremental cost effectiveness ratio. 
Results
All strategies were under the threshold value, which was set as the Korean gross domestic
product of $25,990. In particular, the ‘strong screening recommendation to target regions’
strategy was found to be the most cost effective (incremental cost effectiveness ratio,
7,361,145 Korean won). This was also true when societal inequality aversion increased in
the distributional cost effectiveness analysis. 
Conclusion
The ‘strong screening recommendation to target regions’ strategy was the most cost effec-
tive approach, even when adjusting for inequality. As efficiency and equity are objectives
concurrently sought in healthcare, these findings imply a need to develop appropriate eco-
nomic evaluation methodologies to assess healthcare policies. 
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Introduction
A significant proportion of deaths in South Korea can be
attributed to cancer, with cancer mortality rates being 
reported as 150.9 per 100,000 individuals in 2014 [1]. Cancer
is known to impose large socioeconomic burdens on society
because it incurs substantial direct healthcare costs, as well
as indirect costs such as those associated with caregiving and
lost productivity [2]. To address the burden of cancer, the
South Korean government implemented the National Cancer
Screening Program in 1999 to provide screening for the five
most common sites of cancer; namely, stomach, liver, col-
orectal, breast, and the cervix uteri.   
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The World Health Organization reported that a 93% reduc-
tion in the incidence of cervical cancer can be expected in 
response to introduction of screening programs [3]. More-
over, previous studies have shown that national cervical can-
cer screening is cost effective at reducing cervical cancer
incidence and mortality in South Korea [4,5]. Cho et al. [6]
demonstrated that the national cervical cancer screening pro-
gram was effective in terms of life years saved (LYS), with a
threshold of $32,272 ($1=1,100 Korean won [KRW]) per per-
son, which was the gross domestic product (GDP) of South
Korea in 2012 (incremental cost effectiveness ratio [ICER],
7,581,679 KRW/LYS). Similarly, another study cited the 
annual conduction of Papanicolaou smear cytology (Pap) to
females aged 30 or above as the most cost effective strategy
in quality adjusted life years (QALY) [7]. 
Despite the potential benefits of national cervical cancer
screening uptake, examination rates are reportedly lower in
South Korea (approximately 66%) than in other countries 
including the United States (74%) and the United Kingdom
(78%) [8]. Disparities were also found among individuals of
various socioeconomic status, and particularly among those
of different regional status [8]. Hence, such tendencies 
require the need for a cost effectiveness analysis that takes
into account regional inequality and distribution of health
effects, in addition to previous research that has aimed to
maximize population health using restricted resources [9]. 
Despite such importance, few South Korean studies have
included cost effectiveness analysis of cervical cancer based
on regional disparities in cancer screening. A previous study
targeting Taiwanese participants concluded that individuals
who received group education programs had higher screen-
ing rates than those who received introduction pamphlets
through the mail [10]. Another study in the United States
demonstrated that sending introduction pamphlets by mail
can increase cervical cancer screening rates by about 12%
[11]. Therefore, this study was conducted to evaluate cost 
effectiveness of methods with the aim of identifying strate-
gies that can improve the South Korean national cervical can-
cer screening uptake rate. Further analysis was also per-
formed considering regional disparities in screening rates
using the distributional cost effectiveness analysis method,
which specifically considers health inequalities under the
cost effectiveness framework [12]. 
Materials and Methods
1. Model structure: cost-effectiveness analysis
A Markov simulation model was developed using
TreeAge Pro (TreeAge Software, Williamstown, MA). The
model structure is illustrated in Fig. 1. Individuals enter the
model in a healthy, well state. With time, a proportion of the
individuals are found to be susceptible to human papillo-
mavirus (HPV) infection, which can progress to cervical 
intraepithelial neoplasia (CIN) and cancer.
The model incorporates disease regression, and individu-
als immediately diagnosed with CIN move to the well his-
HPV infectionWell
Well history
Local
Regional
Distant
Cancer cured
Death
CIN 1 CIN 2/3
Fig. 1.  Model of the natural history of cervical cancer. HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia.
Tae-Hoon Lee, Cervical Cancer Screening Distributional Cost-Effectiveness
Ag
e
Se
ou
l
Da
eg
u
Da
eju
n
In
ch
eo
n
Gw
an
gj
u
Ul
sa
n
Gy
eo
ng
gi
Bu
sa
n
(y
r)
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
20
-24
0.0
41
1
0.0
00
2
0.0
40
5
0.0
00
2
0.0
2
0.0
00
2
0.0
41
7
0.0
00
3
0.0
1
0.0
00
3
0.0
59
8
0.0
00
5
0.0
43
0
0.0
00
2
0.0
31
2
0.0
00
3
25
-29
0.1
81
4
0.0
00
3
0.1
53
8
0.0
00
5
0.2
21
5
0.0
00
4
0.2
02
0.0
00
4
0.1
44
5
0.0
00
4
0.1
98
6
0.0
00
3
0.2
20
1
0.0
00
3
0.1
34
7
0.0
00
5
30
-34
0.4
07
6
0.0
00
5
0.3
50
3
0.0
00
5
0.4
53
4
0.0
00
3
0.4
31
4
0.0
00
5
0.3
43
4
0.0
00
5
0.4
12
8
0.0
00
5
0.4
59
1
0.0
00
4
0.4
01
9
0.0
00
6
35
-39
0.5
17
2
0.0
00
5
0.4
97
2
0.0
00
6
0.4
82
1
0.0
00
5
0.5
11
7
0.0
00
5
0.5
17
4
0.0
00
7
0.4
76
5
0.0
00
5
0.5
54
2
0.0
00
5
0.4
42
7
0.0
00
6
40
-44
0.6
36
4
0.0
00
7
0.5
44
4
0.0
00
8
0.6
36
1
0.0
00
9
0.6
13
1
0.0
00
9
0.6
27
7
0.0
00
8
0.6
60
6
0.0
00
9
0.6
59
0
0.0
00
8
0.6
02
4
0.0
00
9
45
-49
0.6
55
7
0.0
01
1
0.6
06
9
0.0
01
1
0.6
99
7
0.0
01
3
0.6
23
2
0.0
01
2
0.6
98
5
0.0
01
1
0.6
57
5
0.0
01
0
0.6
70
5
0.0
01
2
0.6
33
6
0.0
01
3
50
-54
0.6
91
8
0.0
01
4
0.6
54
5
0.0
01
8
0.7
91
2
0.0
01
3
0.6
11
7
0.0
01
6
0.6
91
2
0.0
01
7
0.6
42
6
0.0
01
7
0.6
86
0.0
01
6
0.6
47
2
0.0
01
7
55
-59
0.7
12
6
0.0
01
9
0.6
39
1
0.0
02
0
0.7
40
6
0.0
02
4
0.6
22
7
0.0
02
3
0.6
79
4
0.0
02
3
0.6
20
7
0.0
02
2
0.6
94
0.0
02
3
0.6
59
6
0.0
02
4
60
-64
0.6
83
7
0.0
02
9
0.5
52
7
0.0
03
4
0.6
66
7
0.0
03
6
0.6
17
6
0.0
04
0
0.7
13
5
0.0
03
5
0.6
19
4
0.0
02
5
0.6
41
4
0.0
03
5
0.6
22
3
0.0
03
8
65
-69
0.5
85
4
0.0
05
2
0.4
95
7
0.0
06
5
0.6
39
3
0.0
07
0
0.5
18
6
0.0
06
7
0.5
93
8
0.0
05
9
0.4
35
6
0.0
07
1
0.5
81
1
0.0
06
2
0.6
09
8
0.0
06
6
70
-74
0.5
49
8
0.0
10
5
0.3
79
8
0.0
12
8
0.4
95
6
0.0
12
6
0.4
11
3
0.0
13
3
0.5
50
4
0.0
13
5
0.3
55
6
0.0
16
0.4
83
9
0.0
12
5
0.4
73
6
0.0
14
75
-79
0.3
80
1
0.0
22
5
0.2
47
0
0.0
24
6
0.3
88
2
0.0
26
1
0.3
36
3
0.0
25
9
0.4
43
3
0.0
27
6
0.3
42
9
0.0
30
2
0.3
66
8
0.0
25
0
0.3
50
3
0.0
30
1
80
-84
0.1
97
0.0
80
2
0.1
76
5
0.0
93
6
0.2
97
9
0.0
86
8
0.1
81
8
0.0
85
9
0.1
89
2
0.0
95
1
0.0
60
6
0.1
01
4
0.2
28
4
0.0
83
7
0.1
74
1
0.0
94
0
" 8
5
0.1
11
1
0.0
37
0.2
18
8
0.0
72
3
0.3
91
3
0.0
95
2
0.1
13
0.1
33
3
Ga
ng
wo
n 
Ch
un
gb
uk
Ch
un
gn
am
Je
on
bu
k
Je
on
na
m
Gy
eo
ng
bu
k
Gy
eo
ng
na
m
Je
ju
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
Sc
ree
nin
g
M
ort
ali
ty
20
-24
0.0
63
9
0.0
00
3
0.0
51
9
0.0
00
2
0.0
64
1
0.0
00
4
0.0
14
5
0.0
00
4
0.0
55
8
0.0
00
3
0.0
21
5
0.0
00
3
0.0
26
5
0.0
00
2
0.0
19
6
0.0
00
4
25
-29
0.2
12
9
0.0
00
3
0.2
37
4
0.0
00
5
0.2
16
9
0.0
00
4
0.1
99
1
0.0
00
4
0.1
52
8
0.0
00
4
0.1
68
9
0.0
00
4
0.1
83
8
0.0
00
5
0.1
55
3
0.0
00
8
30
-34
0.4
26
9
0.0
00
6
0.4
09
2
0.0
00
6
0.3
82
4
0.0
00
6
0.3
68
4
0.0
00
5
0.3
21
7
0.0
00
6
0.4
04
8
0.0
00
7
0.4
00
7
0.0
00
7
0.3
45
9
0.0
00
5
35
-39
0.4
91
9
0.0
00
8
0.5
04
7
0.0
00
7
0.4
99
1
0.0
00
6
0.5
09
0
0.0
00
8
0.4
80
3
0.0
00
9
0.4
39
3
0.0
00
7
0.5
09
1
0.0
00
6
0.5
12
6
0.0
00
7
40
-44
0.5
81
9
0.0
01
0
0.6
11
7
0.0
01
1
0.6
12
4
0.0
01
2
0.5
91
9
0.0
01
0
0.6
16
3
0.0
00
9
0.5
63
0.0
01
0.6
30
4
0.0
00
9
0.5
50
6
0.0
01
2
45
-49
0.6
18
5
0.0
01
4
0.6
39
9
0.0
01
3
0.6
54
9
0.0
01
1
0.6
59
6
0.0
01
4
0.6
06
4
0.0
01
3
0.5
70
7
0.0
01
5
0.6
50
1
0.0
01
2
0.6
10
0
0.0
01
6
50
-54
0.6
72
3
0.0
02
1
0.6
76
6
0.0
02
3
0.6
49
1
0.0
01
8
0.6
96
0
0.0
02
1
0.6
34
7
0.0
02
0
0.5
84
3
0.0
01
6
0.6
52
0.0
01
8
0.6
80
9
0.0
01
6
55
-59
0.6
69
0.0
02
6
0.6
87
5
0.0
02
2
0.6
40
4
0.0
02
9
0.6
65
0
0.0
02
8
0.6
57
9
0.0
02
2
0.5
92
1
0.0
02
5
0.6
37
2
0.0
02
4
0.6
33
5
0.0
01
8
60
-64
0.6
23
7
0.0
04
1
0.6
08
9
0.0
04
0
0.6
02
2
0.0
04
3
0.6
84
8
0.0
04
5
0.6
31
0
0.0
03
2
0.5
61
1
0.0
03
5
0.5
89
4
0.0
03
8
0.6
29
3
0.0
03
9
65
-69
0.5
85
1
0.0
06
9
0.5
72
5
0.0
06
7
0.5
41
5
0.0
07
2
0.5
59
2
0.0
06
4
0.6
11
1
0.0
06
8
0.5
02
6
0.0
06
0.4
88
2
0.0
06
6
0.5
00
0
0.0
04
7
70
-74
0.4
89
3
0.0
12
5
0.4
81
4
0.0
12
5
0.4
76
2
0.0
14
7
0.5
45
5
0.0
12
7
0.5
11
5
0.0
12
0
0.4
05
9
0.0
13
0.4
10
7
0.0
12
5
0.3
77
2
0.0
08
7
75
-79
0.3
92
5
0.0
23
9
0.3
58
2
0.0
24
5
0.3
57
9
0.0
26
4
0.4
34
7
0.0
24
0
0.4
81
2
0.0
24
6
0.3
06
3
0.0
25
4
0.2
89
4
0.0
28
3
0.3
00
9
0.0
20
8
80
-84
0.2
35
1
0.0
84
4
0.2
40
2
0.0
79
9
0.1
88
9
0.0
88
8
0.3
00
0
0.0
82
3
0.3
12
2
0.0
83
8
0.1
94
3
0.0
84
9
0.1
76
1
0.0
87
1
0.1
90
9
0.0
73
5
" 8
5
0.1
32
1
0.1
91
7
0.0
98
9
0.1
71
4
0.1
89
5
0.0
76
7
0.0
41
7
0.1
01
4
Ta
bl
e 1
.2
01
2 s
pe
cif
ic 
ce
rv
ica
l c
an
ce
r s
cre
en
in
g a
nd
 m
or
tal
ity
 ra
tes
 ac
co
rd
in
g t
o r
eg
ion
 an
d a
ge
Cancer Res Treat. 2018;50(1):212-221
214 CANCER  RESEARCH  AND  TREATMENT
tory state after treatment. The well history state can lead to
an increase in screening rates as individuals diagnosed with
CIN are likely to become cautious about CIN and cancer. If
cancer progresses, individuals can only move to the cancer
cured state if they receive treatment and survive for 5 years.
These individuals are assumed to be cancer free and consid-
ered to not receive further screening. A death state is present
in each status, and all individuals are transferred to the death
state 100 years after the start of the cohort. 
Because this study aimed to identify strategies that can 
improve screening uptake, four screening strategies were
evaluated: (1) the current strategy, which is the presently fol-
lowed national cancer screening program in South Korea. In
this strategy, all females aged 20 or above receive the Pap
smear test biennially, and individuals screened positive 
obtain further secondary examinations. (2) The strong screen-
ing recommendation to target regions strategy, which, in 
addition to the current strategy, sends strong screening rec-
ommendation posts to target populations residing in areas
with higher than average mean mortality rates. (3) The reg-
ular universal screening recommendation strategy, which
dispatches regular screening recommendation posts to all
target populations. (4) The strong universal screening recom-
mendation strategy, which mails strong screening recom-
mendations to all target populations. The four strategies are
presumed to result in a difference of screening uptake rates:
(1) current: biennial Pap to females aged 20 or above (refer-
ence), (2) strong screening recommendation by mail to target
regions, (effect, 12% increase in screening uptake; cost, 1,000
KRW per person), (3) regular universal screening recommen-
dation by mail, (effect, 6% increase in screening uptake; cost,
500 KRW per person), and (4) strong universal screening rec-
ommendation by mail (effect, 12% increase in screening 
uptake; cost, 1,000 KRW per person).
A cohort of 1,000,000 women aged 20 or above without a
history of cervical cancer was included in the simulation
model because the national cervical cancer screening pro-
gram in South Korea targets this group [13]. The model sim-
ulated each cohort member based on age-specific cervical
cancer incidence and mortality rates. Analysis was con-
ducted using the restricted societal perspective, which 
accounted for direct medical costs, indirect costs, and care-
giving costs, but excluded human productivity costs. 
Mortality rateAge (yr)
1-Year 2-Year 3-Year 4-Year 5-Year
Local
20-29 0.039 0.093 0.127 0.147 0.167
30-39 0.017 0.057 0.089 0.105 0.117
40-49 0.013 0.038 0.062 0.073 0.091
50-59 0.015 0.054 0.089 0.118 0.140
60-69 0.027 0.067 0.114 0.143 0.157
70-79 0.048 0.115 0.146 0.191 0.214
" 80 0.113 0.223 0.357 0.392 0.567
Regional 
20-29 0.177 0.155 0.057 0.000 0.035
30-39 0.100 0.131 0.055 0.043 0.026
40-49 0.087 0.133 0.072 0.035 0.024
50-59 0.090 0.103 0.073 0.034 0.033
60-69 0.082 0.097 0.073 0.042 0.049
70-79 0.107 0.126 0.058 0.069 0.054
" 80 0.206 0.191 0.124 0.079 0.068
Distant 
20-29 0.737 0.058 0.026 0.000 0.040
30-39 0.589 0.206 0.058 0.025 0.070
40-49 0.491 0.190 0.081 0.052 0.026
50-59 0.505 0.195 0.075 0.054 0.011
60-69 0.508 0.195 0.073 0.05 0.000
70-79 0.533 0.153 0.035 0.028 0.022
" 80 0.674 0.089 0.068 0.096 0.002
Table 2. Age- and site-specific cervical cancer mortality rates
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2. Model parameters
Age- and region-specific screening uptake rates were 
obtained from the 2012 Korean Community Health Survey
(KCHS) (Table 1). The KCHS is a nationally representative
survey conducted in 253 local districts of South Korea by the
Korean Centers for Disease Control and Prevention with the
goal of understanding disease prevalence and morbidity pat-
terns. Age- and region-specific mortality rates were calcu-
lated by eliminating cancer mortality rates from the general
mortality rate reported by Statistics Korea in 2012 (Table 1).
Cervical cancer stages were based on the Surveillance, Epi-
demiology, and End Results (SEER). As SEER statistics on
cervical cancer transition probabilities were unavailable, 
International Federation of Gynecology and Obstetrics
(FIGO) stages were converted to SEER stages using statistics
reported in the FIGO annual report [14,15]. Table 2 presents
the age- and stage-specific 5-year mortality rates of cervical
cancer in South Korea. As SEER cancer stage based transition
probabilities were not available in South Korea, this infor-
mation was obtained by converting FIGO cancer stage based
transition probabilities [15]. 
HPV infection rates were attained using simulation results
reported by Ko et al. [7], who took into consideration rate of
HPV infection and sexual experience (Table 3). The CIN tran-
sition probabilities were obtained from the National Health
Insurance data (Table 3) [16]. Parameters pertaining to the
regression probabilities in the precancerous stages were 
obtained from previous cost effectiveness analysis of cervical
cancer in Thailand as no local information was available for
Korea (Table 3) [17,18]. Cervical cancer transition probabili-
ties were calculated by transforming FIGO stages to SEER
stages, as described above (Table 3) [14]. 
3. Costs
Direct and indirect costs were included in this study, as
shown in Table 4 [19,20]. Direct medical costs included those
incurred from the Pap smear test and, with regard to indi-
viduals who screened positive, those associated with col-
poscopy, biopsy, and HPV DNA tests. The average usage
rates of the three examinations were used because informa-
tion regarding the rate of each examination was not avail-
able. Direct tests also included consultation costs and treat-
ment costs for individuals diagnosed with precancerous
states or cancer. Treatment costs were calculated based on a
previous study conducted by Goldhaber-Fiebert because
studies conducted in South Korea did not measure costs by
disease stage [21]. Indirect costs included time, transporta-
tion, and caregiving costs. Discount rates were assumed to
be 1%. 
4. Utilities and screening effects
Age-specific health state utilities were attained using the
EuroQol-5D results of the KCHS. Precancerous state patient
utilities were adjusted using outcomes from patient surveys
[16] and cancer state utilities were calculated based on pre-
vious studies [22,23]. Sensitivity and specificity of the Pap
smear test were determined from a meta-analysis of experi-
mental studies in South Korea [7]. Individuals tested positive
on the Pap smear test were assumed to fully participate in
secondary tests and the sensitivity of secondary tests were
set at 100%. 
Table 3. Cervical cancer screening program model param-
eters
Parameter Value
HPV infection rate
Age (yr)
20-29 0.24
30-39 0.14
40-49 0.13
50-59 0.09
60-69 0.03
" 70 0.01
Precancerous state transition probability
State
CIN1 known $ CIN2/3 known 8.31 
CIN1 unknown $ CIN2/3 unknown 13.00
CIN2/3 known $ Local known 2.14
CIN2/3 unknown $ Local unknown 50.00
Regression rate
Regression state
HPV $ Well
20-24 yr 0.552 
25-29 yr 0.370
" 30 yr 0.103
CIN1 $Well
20-34 yr 0.1449
" 35 yr 0.0738
CIN1 $ HPV
20-34 yr 0.0161
" 35 yr 0.0082
CIN2/3 $ Well 0.0345
CIN2/3 $ CIN1 0.0345
Cancerous state transition probability
State
Local unknown $ Regional unknown 14.8
Regional unknown $ Distant unknown 31.1
HPV, human papillomavirus; CIN, cervical intraepithelial
neoplasia. 
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5. Distributional cost effectiveness analysis
Distributional cost effectiveness analysis aims to adjust the
total effectiveness outcome with an inequality index so that
strategies with larger health disparity result in lower total 
effectiveness [24]. A method for distributional cost effective-
ness has been introduced by the Centre for Health Economics
in 2014, which can be expressed using the Atkinson Inequal-
ity Index in Eq. (1) [12]. The Atkinson Inequality Index is a
function of inequality aversion, namely public aversion to
health disparity, that is measured using public opinion 
regarding the ideal rate of exchange between the health of
individuals with the best and worst health [24]. After calcu-
lating the Atkinson Inequality Index for every intervention
deliberated in this study, the Atkinson ICER can be meas-
ured using Eq. (2), which adjusts the obtained ICER by the
Atkinson Inequality Index [24]. The Atkinson ICER can 
assess which strategy considered in an analysis is the most
cost-effective when inequality aversion increases in a society
[24]. In this study, the Atkinson ICER was used to account
for regional disparities in screening rates and to investigate
health inequalities under the cost effectiveness framework.
Table 4. Cervical cancer screening program cost and util-
ities parameters
Cost Value
Screening costa)
Primary screening costs (total=48,974)
Pap smear test 7,349
Primary diagnosis 15,159
Consultation 5,748
Total 28,256
Transportation (one way) 6,247
Total (#2) 12,494
Time 7,954
Postage of results 270
Secondary costs due to positive 
screening results (total=89,798)
Re-diagnosis 11,395
Specialty consultation 6,267
Total 17,662
Meanb) 32,057
Time (#2) 15,091
Transportation 6,247
Total 24,988
Treatment costsa)
Precancer treatment
CIN1 treatment 2,694,607
CIN2/3 treatment 5,184,292
Cervical cancer treatment
Local 4,585,303
Regional 4,907,512
Distant 7,860,224
Cervical cancer follow up 
management at 1 yr
Local 1,642,859
Regional 1,641,271
Distant 1,650,366
Cervical cancer follow up 
management at 2/3/4 yr
Local 871,275
Regional 870,433
Distant 875,257
Utility
State 
Well or well history 0.763
CIN1 0.714
CIN2/3 0.711
Local 0.496
Regional 0.477
Distant 0.366
Table 4. Continued
Cost Value
Sensitivity and specificity of 
Pap smear test
CIN1 sensitivity 0.77
CIN2/3 sensitivity 0.86
Cancer sensitivity 0.97
Specificity 0.58
CIN, cervical intraepithelial neoplasia. a)All values are in
Korean won (KRW), b)Mean refers to the average colposcopy,
biopsy, and human papillomavirus DNA test costs.
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Results
The results of the cost effectiveness analysis of the four com-
pared strategies are presented in Table 5. The strong universal
screening recommendation strategy had the highest QALY 
effectiveness per person, whereas the current strategy incurred
the lowest amount of cost. With the threshold set at $25,990
(KRW 29,901,550), the 2016 GDP of South Korea, the strong
universal screening recommendation strategy was the most
effective strategy, with an effectiveness of 44.6734 QALY and
an ICER value of KRW 11,506,849. In terms of efficiency, the
strong screening recommendation to target regions was the
most efficient, with an ICER value of KRW 7,361,145. 
Table 6 presents the cost effectiveness analysis results of the
four strategies by the 16 provincial regions of South Korea.
Under the “current” strategy, Seoul had the highest QALYs
per capita, whereas Ulsan showed the lowest QALYs per
capita. Similar tendencies were found under the strong uni-
versal screening recommendation strategy. In the strong
screening recommendation to target regions strategy, Busan
had the highest QALYs per capita and Ulsan the lowest
QALYs per capita. 
Fig. 2 presents the results of the distributional cost effective-
ness analysis, showing the Atkinson ICER of the four strate-
gies examined. When an identical threshold was utilized, the
Atkinson ICER of all four strategies remained under the
threshold value as inequality aversion increased. The cost 
effectiveness of the four strategies also increased as inequality
aversion increased, in particular that of the strong screening
recommendation to target regions strategy. 
Discussion
Studies have demonstrated that the national cervical can-
cer screening program in South Korea is cost effective [4-7].
However, screening uptake rates remain low compared to
other more economically developed countries and show 
regional disparities, requiring implementation of effective
strategies for improvement. To the best of our knowledge,
this is the first study to investigate the required strategies
through a cost effectiveness analysis in South Korea. Previ-
ous studies have examined investments in educational pro-
fessionals, local community group education, mailing of
pamphlets, and consultation volunteers as approaches to 
enhance screening rates and found mailings of pamphlets
and consultation volunteers to be effective [10,11,25]. Con-
sidering the requisite resources of the four approaches inves-
tigated, mailing of pamphlets was selected as a realistic and
applicable scheme. Hence, this study investigated the cost 
effectiveness of four strategies, current, strong screening rec-
ommendation to target regions, regular universal screening
recommendation, and strong universal screening recommen-
dation. The results indicated that the ICER values of all four
strategies were under the threshold value of $25,990 (KRW
29,901,550), and that the strong screening recommendation
to target regions had the highest efficiency, whereas the
strong universal screening recommendation had the highest
effectiveness. Therefore, all four strategies investigated rated
within the ICER threshold value and may be utilized by pol-
icy makers focusing on effectiveness or efficiency. 
Another aspect to contemplate by policy makers is the con-
ceivable effect of each strategy on regional disparity because
South Korea shows discrepancies between regions in 
national cervical cancer screening rates. This was reflected
using the Atkinson ICER, which indicated the strong screen-
ing recommendation to target regions strategy was the most
efficient. The ICER value of this strategy decreased the most;
thus, its cost effectiveness can be seen to have improved com-
Table 5. Costs, QALY, and ICER per capita of national cervical cancer screening program strategies
Variable Costa) Incremental Effectiveness Incremental ICERcosta) effect
Current (baseline) 25,661,227 - 44.5874 - -
Strong recommendation to target regions 26,021,187 359,960 44.6363 0.0489 7,361,145
Regular universal screening recommendation 26,169,410 508,183 44.6466 0.0592 8,584,172
Strong universal screening recommendation 26,650,816 989,589 44.6734 0.086 11,506,849
QALY, quality adjusted life years; ICER, incremental cost effectiveness ratio; CIN, cervical intraepithelial neoplasia. a)Costs
are in Korean won (KRW).
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pared to other strategies. This results as the change in the 
denominator of the Atkinson ICER (%E) decreases for strate-
gies more unequal to the ‘current’ strategy and increases for
strategies less unequal to the “current” strategy. The tenden-
cies presented in the study findings are similar to those of a
previous study that investigated the distributional cost effec-
tiveness of the national colorectal cancer screening program
[24]. This study also found the strong screening recommen-
dation to target regions strategy to be most efficient [24].
However, the ICER value decreased in a comparatively steep
manner as inequality aversion increased, revealing that
health disparities are likely to decline in a comparatively
larger amount if the strong screening recommendation to tar-
get regions strategy is implemented. 
The findings of this study revealed that addressing health
inequality aversion can be important in the process of fram-
ing health policies. This study offers new insights by inves-
tigating the distributional cost effectiveness of the national
cervical cancer screening program in South Korea. It is also
unique in that it examined different strategies applicable
with the goal of improving national cervical cancer screening
rates because screening rates in South Korea have been 
reported to be relatively low, despite its proven cost effec-
tiveness. However, this study also had its limitations. Specif-
ically, age- and region-specific national cervical cancer
screening rates were obtained from the KCHS because no
other data were available. The KCHS does not distinguish
between public and private cervical cancer screening, and
screening rates may have been overestimated, which also 
infers a possible overestimation of the cost measures used in
this study. Second, HPV infection, precancerous, and cancer
transition probabilities data were not based on South Korean
data because they were unavailable. Hence, cost and effec-
tiveness may have again been overestimated as sexual
lifestyles tend to be more conservative in South Korea than
in other Western countries [16]. Third, although it can be 
assumed that disease transition probabilities will differ 
between regions, our study was unable to account for such
characteristics because of a lack of data. These assumptions
may have led to underestimation of the inequality measured.
This limitation has also been mentioned in previous studies
and necessitates the measurement of inequality variables. 
Finally, because this study is the first distributional cost 
effectiveness study of the national cervical cancer screening
program in South Korea, no other results were available to
compare with the findings presented. 
In conclusion, analysis of the cost effectiveness of the 
national cervical cancer screening program in South Korea
revealed the strong screening recommendation to target 
regions strategy to be the most cost effective approach. Sim-
ilar tendencies were found when societal inequality aversion
increased under the distributional cost effectiveness analysis,
which accounted for regional disparities in screening uptake
rates. As efficiency and equity are the two main objectives
concurrently sought in healthcare, the findings of this study
imply the need to develop appropriate economic evaluation
methodologies to assess healthcare policies. 
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